A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer's Disease

Current Alzheimer Research

Volumn 11, Issue 1, 2014, Pages 47-58

  Grove, Richard A ^a   Harrington, Conn M ^b   Mahler, Andreas ^c   Beresford, Isabel ^a   Maruff, Paul ^d   Lowy, Martin T ^b   Nicholls, Andrew P ^a,c   Boardley, Rebecca L ^a   Berges, Alienor C ^a   Nathan, Pradeep J ^a,e   Horrigan, Joseph P ^a,f  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c CogState Ltd ^*  (United Kingdom)

^d Clinical Unit ^*  (Australia)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f Neuren Pharmaceuticals Limited   (United Kingdom)

Author keywords

Alzheimer's disease; Attention; Cognition; Episodic memory; Executive function; H3 receptor antagonist; Histamine

Indexed keywords

GSK 239512; GSK239512; HISTAMINE H3 RECEPTOR ANTAGONIST; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NEUROPSYCHOLOGICAL TEST; NIGHTMARE; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RIB FRACTURE; URINARY TRACT INFECTION; VERY ELDERLY; WORKING MEMORY;

AGED; ALZHEIMER DISEASE; BENZAZEPINES; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MALE; MEDICATION ADHERENCE; MEMORY, EPISODIC; MEMORY, SHORT-TERM; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84891763528     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205010666131212110148     Document Type: Article

References (38)

1. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 6(2): 98-103 (2010).
2. Rogers S, Farlow M, Doody R, Mohs R, Friedhoff L, and the Donepezil Study Group. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145 (1998).
3. Raina P, Santaguida P, Ismaila P, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148: 379-397 (2008).
4. 3) visualized in the brain of human and non-human primates. Brain Res 526(2): 322-7 (1990).
5. 3 receptors in rat brain areas. Neurosci 52(1): 169-89 (1993).
6. 3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321(3): 1032-45 (2007).
7. 3) of histamine receptor. Nature 302(5911): 832-7 (1983).
8. 3 receptor subtypes. Br J Pharmacol 107(4): 919-23 (1992).
9. 3 receptor activation in rats. Br J Pharmacol 119(8): 1656-64 (1996).
10. 3-receptor antagonist. J Pharmacol Exp Ther 287(2): 658-66 (1998).
11. 3 receptor: A target for new drugs. Amsterdam: Elsevier: 13-26 (1998).
12. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 63(6): 637-72 (2001).
13. 3 receptor antagonist. J Pharmacol Exp Ther 313(1): 176-90 (2005).
14. 3 receptors in Alzheimer's disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol 157(1): 130-8 (2009).
15. 3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. JPET 336: 38-45 (2011).
16. Passani MB, Blandina P. Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32(4): 242-9 (2011).
17. 3 receptor antagonists. Bioorg Med Chem Lett 23(24): 6890-6 (2013).
18. 3 receptor antagonist in patients with mild to moderate Alzheimer's disease. Curr Alzheimer Res 10(3): 240-251 (2013).
19. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State A practical method for grading the cognitive state of patients for the clinician. J Psych Res 12: 189-198 (1975).
20. 3 receptor in humans using PET. J Nucl Med 51(7): 1021-9 (2010).
21. Ellis KA, Bush AI, Darby D, De Fazio D, Foster J, Hudson P, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 21(4): 672-87 (2009).
22. Lim YY, Ellis KA, Harrington K, Ames D, Martins RN, Masters CL, et al. Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. J Clin Exp Neuropsychol 34(4): 345-58 (2012).
23. Lim YY, Pietrzak RH, Snyder PJ, Darby D, Maruff P. Preliminary data on the effect of culture on the assessment of Alzheimer's disease- related verbal memory impairment with the International Shopping List Test. Arch Clin Neuropsychol 27(2): 136-47 (2012).
24. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiat 141: 1356-64 (1984).
25. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-14 (1994).
26. Gelinas I, Gauthier L, McIntyre, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 53: 471-81 (1999).
27. Schneider L, Olin J, Doody R, Clark C, Morris J, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 11(2): S22-S32 (1997).
28. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 218-22, 534-37 (1976).
29. Buysse DJ, Reynolds III CF, Monk TH, Berman, SR, Kupfer, DJ. Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213 (1989).
30. Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 14(6): 540-5 (1991).
31. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology 7: 436-450 (2008).
32. Irizzary M, Webb D, Bains C, Barrett S, Lai R, Laroche J, et al. Predictors of placebo group decline in the Alzheimer's Disease Scale-Cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease. J Alzheimers Dis 14: 301-311 (2008).
33. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharmaceut Statist 7: 93-106 (2008).
34. Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry 21(1): 17-28 (2006).
35. 3 receptor antagonists: from target identification to drug leads. Biochem Pharmacol 73(8): 1084-96 (2007).
36. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, et al. JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacol 56(8): 1131-7 (2009).
37. Cho W, Maruff P, Connell J, Gargano C, Calder N, Doran S, et al. Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacol 218(3): 513-24 (2011).
38. Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, et al. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr Alzheimer Res 9: 481-490 (2012).